151 related articles for article (PubMed ID: 30343311)
21. Macrophage migration inhibitory factor in obese and non obese women with polycystic ovary syndrome.
Mejia-Montilla J; Álvarez-Mon M; Reyna-Villasmil E; Torres-Cepeda D; Santos-Bolívar J; Reyna-Villasmil N; Suarez-Torres I; Bravo-Henríquez A
Endocrinol Nutr; 2015 Jan; 62(1):31-7. PubMed ID: 25458401
[TBL] [Abstract][Full Text] [Related]
22. GH release after GHRH plus arginine administration in obese and overweight women with polycystic ovary syndrome.
Orio F; Palomba S; Colao A; Russo T; Dentico C; Tauchmanovà L; Savastano S; Nappi C; Sultan C; Zullo F; Lombardi G
J Endocrinol Invest; 2003 Feb; 26(2):117-22. PubMed ID: 12739737
[TBL] [Abstract][Full Text] [Related]
23. Serum neudesin levels in patients with polycystic ovary syndrome.
Yilmaz Yasar H; Demirpence M; Colak A; Zeytinli M; Yasar E; Taylan A
Ginekol Pol; 2022; 93(7):525-530. PubMed ID: 34263912
[TBL] [Abstract][Full Text] [Related]
24. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
Ganie MA; Khurana ML; Nisar S; Shah PA; Shah ZA; Kulshrestha B; Gupta N; Zargar MA; Wani TA; Mudasir S; Mir FA; Taing S
J Clin Endocrinol Metab; 2013 Sep; 98(9):3599-607. PubMed ID: 23846820
[TBL] [Abstract][Full Text] [Related]
25. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
[TBL] [Abstract][Full Text] [Related]
26. Phenotypic expression, body mass index and insulin resistance in relation to LH levels in women with polycystic ovary syndrome.
Katsikis I; Karkanaki A; Misichronis G; Delkos D; Kandaraki EA; Panidis D
Eur J Obstet Gynecol Reprod Biol; 2011 Jun; 156(2):181-5. PubMed ID: 21353371
[TBL] [Abstract][Full Text] [Related]
27. High serum concentration of total inhibin in polycystic ovary syndrome.
Tsigkou A; Luisi S; De Leo V; Patton L; Gambineri A; Reis FM; Pasquali R; Petraglia F
Fertil Steril; 2008 Nov; 90(5):1859-63. PubMed ID: 18423626
[TBL] [Abstract][Full Text] [Related]
28. Galanin-like peptide and its correlation with androgen levels in patients with polycystic ovary syndrome.
Demirpence M; Yilmaz Yasar H; Karakoyun I; Girgin EM
Endokrynol Pol; 2023; 74(2):197-202. PubMed ID: 37155301
[TBL] [Abstract][Full Text] [Related]
29. The impact of serum adropin and ischemia modified albumin levels based on BMI in PCOS.
Inal ZO; Erdem S; Gederet Y; Duran C; Kucukaydin Z; Kurku H; Sakarya DK
Endokrynol Pol; 2018; 69(2):135-141. PubMed ID: 29465156
[TBL] [Abstract][Full Text] [Related]
30. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome.
Yildiz BO; Yarali H; Oguz H; Bayraktar M
J Clin Endocrinol Metab; 2003 May; 88(5):2031-6. PubMed ID: 12727950
[TBL] [Abstract][Full Text] [Related]
31. [Obesity, hormonal and metabolic abnormalities in adolescent girls with polycystic ovary syndrome].
Ságodi L; Lombay B; Vámosi I; Barkai L
Orv Hetil; 2013 Aug; 154(31):1226-34. PubMed ID: 23895991
[TBL] [Abstract][Full Text] [Related]
32. Serum Amyloid A is a Novel Inflammatory Biomarker in Polycystic Ovary Syndrome.
Sun Y; Chen X; Ouyang B; Pan G; Sun L; Li S; Chen K
Clin Lab; 2019 May; 65(5):. PubMed ID: 31115233
[TBL] [Abstract][Full Text] [Related]
33. Serum HLA-G levels in women with polycystic ovary syndrome.
Oztekin O; Fenkci SM; Fenkci V; Enli Y; Cabus U
Gynecol Endocrinol; 2015 Mar; 31(3):243-6. PubMed ID: 25403326
[TBL] [Abstract][Full Text] [Related]
34. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.
Morales AJ; Laughlin GA; Bützow T; Maheshwari H; Baumann G; Yen SS
J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842
[TBL] [Abstract][Full Text] [Related]
35. Insulin resistance in nonobese patients with polycystic ovary syndrome.
Toprak S; Yönem A; Cakir B; Güler S; Azal O; Ozata M; Corakçi A
Horm Res; 2001; 55(2):65-70. PubMed ID: 11509861
[TBL] [Abstract][Full Text] [Related]
36. Serum testosterone predicts cardiorespiratory fitness impairment in normal-weight women with polycystic ovary syndrome.
Bacchi E; Negri C; Di Sarra D; Tosi F; Tarperi C; Moretta R; Schena F; Bonora E; Kaufman JM; Moghetti P
Clin Endocrinol (Oxf); 2015 Dec; 83(6):895-901. PubMed ID: 26173542
[TBL] [Abstract][Full Text] [Related]
37. Serum leptin levels correlate with clinical and biochemical indices of insulin resistance in women with polycystic ovary syndrome.
Pehlivanov B; Mitkov M
Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):153-9. PubMed ID: 19340711
[TBL] [Abstract][Full Text] [Related]
38. [Effect of luteinizing hormone vs follicular stimulating hormone ratio on anti-Müllerian hormone secretion and folliculogenesis in patients with polycystic ovarian syndrome].
Li Y; Wei LN; Xiong YL; Liang XY
Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):567-70. PubMed ID: 21029609
[TBL] [Abstract][Full Text] [Related]
39. Serum C-reactive protein (CRP) levels and insulin resistance in non-obese women with polycystic ovarian syndrome, and effect of bicalutamide on hirsutism, CRP levels and insulin resistance.
Bahceci M; Tuzcu A; Canoruc N; Tuzun Y; Kidir V; Aslan C
Horm Res; 2004; 62(6):283-7. PubMed ID: 15542929
[TBL] [Abstract][Full Text] [Related]
40. The relationship between thyroid function and metabolic changes in Chinese women with polycystic ovary syndrome.
Yin D; Ruan X; Tian X; Du J; Zhao Y; Cui Y; Li Y; Mueck AO
Gynecol Endocrinol; 2017 Apr; 33(4):332-335. PubMed ID: 28051891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
